CCA Industries settles Mega-T suit
This article was originally published in The Tan Sheet
The marketer of Mega-T brand weight-loss supplements sets aside $2.5 million to distribute among consumers who purchased Mega-T brand products between Sept. 29, 2005, and June 9, 2010. The Common Fund settles a class action lawsuit brought by Denise Wally in California's Superior Court for Los Angeles County. Wally alleged the firm falsely advertised that the supplements would "reduce food cravings," help consumers "lose up to 20 lbs" and enable consumers to burn belly fat without diet or exercise. Consumers who bought any of the supplements in the settlement, including Mega-T Ultra, Mega-T Plus, Mega-T Effervescent, Mega-T Green Tea dietary supplement and Mega-T Dietary Supplement products, could receive up to $60 or more if they submit a claim form. CCA Industries does not admit any guilt or wrongdoing in the settlement. FTC often penalizes weight-loss product makers for claiming products help consumers lose weight without exercise (1"The Tan Sheet" Feb. 22, 2010, In Brief)
You may also be interested in...
Artis Marketing says it will discontinue and modify advertising claims for its SlimForce7 weight-loss product following a recommendation by the National Advertising Division and referral to the Federal Trade Commission. The division of the Council of Better Business Bureaus found insufficient evidence to support the claim the product is a "treatment aimed at all those who can't seem to lose all the weight they want to lose," among other claims. NAD recommended the Toronto-based company discontinue testimonials and claims suggesting the product, made of six fruits and one algae, will result in weight loss regardless of diet and exercise. NAD's review of SlimForce7 follows a previous attempt to review claims for the product, after which the watchdog was unable to contact the advertiser and referred it to FTC, FDA and relevant Canadian agencies (1"The Tan Sheet" Aug. 17, 2009, In Brief). Subsequently, Artis agreed to participate in the review process, noting it permanently discontinued the original ads and modified many claims at issue. However, NAD found many of the modified claims presented similar concerns
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.
Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.